Form 8-K - Current report:
SEC Accession No. 0001193125-25-075100
Filing Date
2025-04-08
Accepted
2025-04-08 07:30:22
Documents
14
Period of Report
2025-04-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d829369d8k.htm   iXBRL 8-K 32445
2 EX-99.1 d829369dex991.htm EX-99.1 9835
  Complete submission text file 0001193125-25-075100.txt   174381

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kalv-20250408.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20250408_lab.xml EX-101.LAB 18756
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20250408_pre.xml EX-101.PRE 11711
16 EXTRACTED XBRL INSTANCE DOCUMENT d829369d8k_htm.xml XML 3775
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 25820279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)